Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.

Su Jin JeongSeung Eun LeeDong Hyun ShinIe Byung ParkHui Seung LeeKyoung-Ah Kim

Published in: BMC nephrology (2021)

Only 32.9 % of T2D with CKD eligible for SGLT2i is currently treated with SGLT2i in real-world clinical practice. The older patient group and clinical inertia are the main barriers to initiate SGLT2i for eligible patients. Clinicians should change the glucocentric approach and focus on reducing renal events in T2D.

Keyphrases

end stage renal disease
chronic kidney disease
clinical practice
newly diagnosed
ejection fraction
physical activity
peritoneal dialysis
case report
patient reported outcomes
community dwelling